Acquired Blepharoptosis Clinical Trial
Official title:
A Phase 1/2a Study of LEV102 Topical Gel in Subjects With Acquired Blepharoptosis
Phase 1/2a, multicenter, randomized, vehicle-controlled, double-masked, multiple-dose, parallel-group study conducted in adult subjects with acquired blepharoptosis.
This is a Phase 1/2a, multicenter, randomized, vehicle-controlled, double-masked, single-dose, parallel-group study conducted in adult subjects with acquired blepharoptosis. Subjects will receive a one-time application of randomized, double-masked IP. Approximately 30 subjects will be enrolled in this study. Eligible subjects will be randomized to 1 of the following 3 treatment groups in a 1:1:1 ratio and will receive a single dose of double-masked IP externally on the upper eyelid of both eyes (OU): ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02436759 -
Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
|
Phase 3 |